In accordance with existing literature and our empirical observations, it has been established that at least 80% of individuals carrying GATA2 mutations develop MDS at an estimated age of 17–20 years11–15, which may subsequently progress to acute myeloid leukemia (AML)16. The gene discussed is GATA2; the disease is myelodysplastic syndrome.